1. Volume 77, Issue 3, Pages 247-255 (February 2010)
Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02V-adjuvanted hepatitis B vaccine 
Murielle Surquin, Christian L. Tielemans, Imre Kulcsár, Miroslav Ryba, Péter Vörös, Olivier Mat, Serge Treille, Michel Dhaene, Jean- Claude Stolear, Sherine O. Kuriyakose, Maarten X. Leyssen, Sophie A. Houard 
Kidney International 
Volume 77, Issue 3, Pages (February 2010)
DOI: /ki
Copyright © 2010 International Society of Nephrology Terms and Conditions

2. Figure 1
Subject flowchart. HB-AS02, hepatitis B virus (HBV) vaccine adjuvanted with AS02; HB-AS04, HBV vaccine adjuvanted with AS04. *This fatal serious adverse event (SAE) started during the primary vaccination study and the subject died the day after the month 7 visit. **These events were not classed as fatal SAEs, as they occurred out of study.
Kidney International  , DOI: ( /ki )
Copyright © 2010 International Society of Nephrology Terms and Conditions

3. Figure 2
The proportion of subjects achieving anti-HBs antibody concentrations of ≥100 mIU/ml over time (total vaccinated cohort). HB-AS02, hepatitis B virus (HBV) vaccine adjuvanted with AS02; HB-AS04, HBV vaccine adjuvanted with AS04.
Kidney International  , DOI: ( /ki )
Copyright © 2010 International Society of Nephrology Terms and Conditions

4. Figure 3
Evolution of anti-HBs antibody geometric mean concentrations (GMCs) over time with 95% confidence intervals (CIs; total vaccinated cohort). HB-AS02, hepatitis B virus (HBV) vaccine adjuvanted with AS02; HB-AS04, HBV vaccine adjuvanted with AS04.
Kidney International  , DOI: ( /ki )
Copyright © 2010 International Society of Nephrology Terms and Conditions